Hope Medicine Inc. announced first patient dosing in a Phase III clinical study evaluating HMI-115, its first-in-class monoclonal antibody, for moderate-to-severe endometriosis-associated pain in China – advancing the globally unique non-hormonal therapy that has secured Fast Track Designation (FTD) in the US and Breakthrough Therapy Designation (BTD) in China toward potential regulatory approval.
Clinical Milestone
Item
Detail
Study
Phase III (multicenter, randomized, double-blind, placebo-controlled)
Product
HMI-115 – first-in-class monoclonal antibody
Company
Hope Medicine Inc. (China-based)
Indication
Moderate-to-severe pain associated with endometriosis
Treatment Period
24 weeks
First Patient Dosed
March 2026
Global Positioning
Only non-hormonal therapy for endometriosis in Phase III globally
Regulatory Designations & Differentiation
Designation
Authority
Significance
Fast Track Designation (FTD)
US FDA
Expedited review for serious conditions with unmet medical need
First-in-class monoclonal antibody with unique mechanism
Market Impact & Outlook
Endometriosis Market Dynamics: Global endometriosis therapeutics US$2-3 billion annually; pain management segment US$1.5-2 billion; non-hormonal therapies represent <5% of market due to lack of approved options; HMI-115’s hormone-sparing profile could capture 30-40% of market (patients seeking fertility preservation or intolerant to hormonal side effects).
China Market Strategy: Phase III China-first development supports CDE BTD pathway; domestic innovation positioning may accelerate NMPA approval (2028-2029); China represents largest endometriosis population globally (~30 million diagnosed cases); pricing flexibility vs. import dependency.
US Regulatory Trajectory: FTD supports rolling NDA submission; Phase III data may enable priority review (6-month FDA timeline); US market entry 2029-2030 assuming positive Phase III; partnership with US commercialization partner likely (Abbott, Myovant, or global pharma).
Global Expansion Potential: EU EMA submission 2028-2029; Japan PMDA 2029-2030; estimated US$1-1.5 billion global peak sales (2032-2035) assuming 25-30% market share in non-hormonal segment; licensing deal potential US$300-500 million upfront for ex-China rights upon Phase III interim data.
Hope Medicine Platform Validation: HMI-115 lead asset validates monoclonal antibody discovery platform; pipeline expansion to other gynecological conditions (uterine fibroids, adenomyosis) using similar mechanism; potential for combination with hormonal therapies for severe disease.
Forward-Looking Statements This brief contains forward-looking statements regarding clinical development timelines, regulatory pathway expectations, and commercial projections for HMI-115. Actual results may differ due to Phase III trial outcomes, competitive dynamics with emerging non-hormonal therapies, and manufacturing scale-up for monoclonal antibody production.-Fineline Info & Tech
By Fineline Cube